Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING : revenue, balance sheet and financial ratios

EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is a French company founded 19 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in NANTES (44300), this company of category GE shows in 2024 a net income negative of -2.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING (SIREN 490500352)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net income -2 446 341 € -29 097 855 € 9 094 685 € 11 837 507 € -136 900 € 3 697 462 € 1 834 900 € 1 359 458 € 5 477 521 €
EBITDA -151 452 € -14 055 € -12 495 € -14 386 € -15 529 € -10 991 € -99 310 € -12 021 € -12 362 €
Net margin N/C N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2024, EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING records a net loss of 2.4 M€. This deficit will reduce equity on the balance sheet.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-151 452 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-151 326 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-2 446 341 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 100%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

99.989%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 9.99
Q3: 48.5
Excellent

In 2024, the debt ratio of EUROFINS BIOPHARMA PRODUC... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
99.99% 2024
2022
2023
2024
Q1: 11.63%
Med: 34.78%
Q3: 58.76%
Excellent +7 pts over 3 years

In 2024, the financial autonomy of EUROFINS BIOPHARMA PRODUC... (100.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.87 years
Excellent -26 pts over 3 years

In 2024, the repayment capacity of EUROFINS BIOPHARMA PRODUC... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 72669.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

72669.155

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-8268.626

Liquidity indicators evolution
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING

Sector positioning

Liquidity ratio
72669.15 2024
2022
2023
2024
Q1: 133.14
Med: 205.95
Q3: 337.03
Excellent

In 2024, the liquidity ratio of EUROFINS BIOPHARMA PRODUC... (72669.15) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-8268.63x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.02x
Q3: 2.48x
Watch -23 pts over 3 years

In 2024, the interest coverage of EUROFINS BIOPHARMA PRODUC... (-8268.6x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. Favorable situation: supplier credit is longer than customer credit by 26 days.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

26 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING

Positioning of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING in its sector

Comparison with sector Analyses, essais et inspections techniques

Similar companies (Analyses, essais et inspections techniques)

Compare EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Analyses, essais et inspections techniques

Frequently asked questions about EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING

What is the revenue of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?

The revenue of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is not publicly disclosed (confidential accounts filed with INPI).

Is EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING profitable?

EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING recorded a net loss in 2024.

Where is the headquarters of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?

The headquarters of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is located in NANTES (44300), in the department Loire-Atlantique.

Where to find the tax return of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?

The tax return of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING operate?

EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.